Advocating for Demonstration of Disease Modification—Have We Been Approaching Clinical Trials in Early Alzheimer Disease Incorrectly?
Vincent Planche, Nicolas Villain
Abstract
This Viewpoint discusses the benefits of clinical trials with a delayed-start design and analysis of downstream biomarkers to examine whether antimyeloid immunotherapy changes the course of early Alzheimer disease.
Topics & Concepts
DiseaseClinical trialMedicineAlzheimer's diseaseImmunotherapyPsychologyIntensive care medicineInternal medicineImmunologyImmune systemAlzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms